Plug Power Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Plug Power Inc trades at $1.75 (market cap $2.42B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.37 (market cap $2.27B). The key difference: Plug Power Inc and SELLAS Life Sciences Group Inc. Common Stock are close in size by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals.
| PLUG | SLS | |
|---|---|---|
Market Cap | $2.42B | $2.27B |
Volume | 53,851,702 | 4,179,659 |
Sector | Industrials | Health |
52-Week High | $4.14 | $15.46 |
52-Week Low | $1.73 | $1.39 |
Typical Hold Time | 41 Days | — |
Enterprise Value | $3.29B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
Plug Power (PLUG) trades at $1.78, down 4.3% today, reflecting ongoing operational challenges despite recent strategic partnerships. The stock shows bearish technical signals with negative moving averages, while fundamentally the company continues to report significant losses with a -220.59% net income margin and negative cash flow. Recent news highlights a major 280 MW electrolyzer agreement with Arcadia eFuels and expansion in Australia/New Zealand, providing potential growth catalysts amid persistent financial headwinds.
The outlook remains challenging with substantial execution risks, though analyst consensus suggests 75% upside to the $3.13 price target. Key risks include continued cash burn, high debt levels, and competitive pressure in the hydrogen sector. Investment appeal depends on successful commercialization of green hydrogen projects and path to profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →